July 23, 2025

Figure 1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

MAIN FINDING: Chemoimmunotherapy shows significant differences in outcomes for patients with low PD-L1 expression.
KEY EVIDENCE: Kaplan–Meier curves indicate overall survival and progression-free survival for 550 patients based on treatment types.
APPROACH: Patients were adjusted by propensity score matching to compare ICI plus chemotherapy against standard chemotherapy.
SIGNIFICANCE: Understanding these outcomes helps guide treatment decisions for advanced lung cancer patients.

Implication

Kaplan–Meier curves estimate OS and PFS in 550 advanced non-small cell lung cancer patients receiving ICI or chemotherapy, suggesting relevant treatment insights.

Abstract

Treatment outcomes adjusted by PSM in all patients. The Kaplan–Meier curves provide estimates of OS (A) and PFS (B) of the 550 patients stratified by treatment with ICI plus chemotherapy (ICI–Chemo) and platinum-based chemotherapy (Chemo).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hata et al. (2025) studied this question.

synapsesocial.com/papers/689a0621e6551bb0af8cdb9b https://doi.org/10.1158/2767-9764.29624069

View Full Paper

Ask AI

Bookmark

Implication

Kaplan–Meier curves estimate OS and PFS in 550 advanced non-small cell lung cancer patients receiving ICI or chemotherapy, suggesting relevant treatment insights.

Figure 1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure 1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading